Elizabeth Smyth MDConsultant Medical Oncologist, Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Elizabeth (Lizzy) Smyth graduated from University College Dublin, Ireland in 2002. She commenced her oncology training in Dublin, Ireland and in 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she was awarded the Irish Health Service Executive Richard Steevenson Scholarship to complete her training at the Royal Marsden Hospital in London. She completed an MSc in Clinical Trials in 2011 (University of London) and was awarded an MD(Res) from the Institute of Cancer Research in 2018.
Dr. Smyth works as a consultant medical oncologist in upper GI oncology at Oxford University NHS Foundation trust with a research focus in oesophagogastric cancer. Her interests are clinical trials and translational research, and she has worked on trial design and management of national and international investigator initiated trials.
Dr. Smyth has published more than 170 peer reviewed manuscripts in her field, including in high impact journals. She is a member of the European Society for Medical Oncology Upper GI Faculty, Chair of the ESMO OncologyPro Working Group, Chair of the ESMO International Societies Committee and a member of the ESMO Council. She is the senior author of both recent ESMO Gastric Cancer and Oesophageal Cancer Guidelines.
Dr. Smyth is the current co-chair of the EORTC GI Trials Group Gastric Cancer Taskforce (2021 – 2024) and the Chair Elect for the EORTC Gastrointestinal Tumour Clinical Trials Group (2024-27). In 2022, Dr. Smyth was a founding member of the UK & Ireland Oesophagogastric Cancer Group (UKIOG) and is a trustee of the UKIOG Charity. She is committed to furthering national and international collaboration in GI trials research and improving outcomes for patients with oesophagogastric cancer.
Recent Contributions to PracticeUpdate:
- 2023 Top Story in Oncology: Use of Immune Checkpoint Inhibitors in Operable Gastroesophageal Cancer Based on the KEYNOTE-585 and MATTERHORN Trial Results
- ESMO 2023: Recommendations From Dr. Elizabeth Smyth for Gastrointestinal Cancer
- ICIs Plus FLOT, SOX, or XELOX Chemotherapy for Locally Advanced G/GEJ Cancer
- Pembrolizumab for Advanced HER2-Negative Gastric or Gastroesophageal Junction (G/GEJ) Cancer
- ASCO 2023: Abstract Recommendations From Dr. Elizabeth Smyth for Gastrointestinal Cancer
- Antibody Drug Conjugates for Gastric Cancer
- Margetuximab Along With Retifanlimab in High Expressing HER2+ Gastric Cancer
- CAR-T Cell Therapy Against Claudin 18.2 for GI Cancers
- Impact of Tumor Neoantigen Vaccine Mediated Specific T-Cell Response Towards Response to Therapy
- Adding First-Line Nivolumab to Chemotherapy for Advanced Gastric, GE Junction, and Esophageal Adenocarcinomas